At Evopoint, we are committed to integrating novel and emerging technologies across diverse discovery platforms and modalities.
Evopoint adopts a disease-centered approach. We identify and establish the optimal technology platforms and modalities tailored to our desired target, indication, and patient population to ensure efficacy, safety, and druggability of candidate therapies.
Small Molecule Drug Discovery Platform
Leveraging multi-omics, functional screening, and a high-efficiency medicinal chemistry engine to create precision therapies targeting key pathways in epigenetics, synthetic lethality, and MDR infections.
Novel Antibody Discovery Platform
Engineering next-generation antibody therapeutics (e.g., ADCs, bispecifics, TCEs) to achieve pinpoint precision and expanded therapeutic windows against refractory solid tumors like pancreatic and gastric cancer.
Targeted Protein Degradation (TPD) Platform
Pioneering a next-generation TPD platform to unlock the "undruggable" proteome by developing highly selective, orally bioavailable protein degraders.
